WSJ today - Bristol Myers paying roughly $6 billion for Mirati - an oncology focused biotech. the article referenced that it's not yet approved, but had results in late-stage study. Further evidence that we are sitting on a very valuable asset - but until we get our internal house in order, it's "gold in the mine".

Come on CYDY - let's get a deal-maker in that CEO seat, and start moving us in that direction!